Patents Assigned to ONO Pharmaceutical Co., Ltd.
-
Publication number: 20230014137Abstract: A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY): wherein all symbols represent the same meaning as described in the specification, and which is useful as a preventive and/or therapeutic agent for, e.g., essential thrombocythemia or reactive thrombocytosis.Type: ApplicationFiled: November 27, 2020Publication date: January 19, 2023Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Yuzo IWAKI, Toshimitsu ENDO, Kensuke KUSUMI
-
Publication number: 20220388955Abstract: A drug containing, as an active ingredient, a compound having an antagonistic activity against an EP2 receptor in the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, of formula (I-A): wherein all symbols have the same meanings as those described in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 26, 2020Publication date: December 8, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akio WATANABE, Atsushi YOSHIDA, Yasuo HIROOKA, Michael G. YANG, Ning LI
-
Patent number: 11512087Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: GrantFiled: June 27, 2019Date of Patent: November 29, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Hiroshi Tokura, Masakuni Kurono, Yoshinori Nomura, Shingo Hotta
-
Publication number: 20220372148Abstract: An agent for preventing, suppressing the progression of symptoms of or the recurrence of, and/or treating hematological cancer, including a protein having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, such as a PD-1/CD3 bispecific antibody or antibody fragment thereof.Type: ApplicationFiled: July 3, 2020Publication date: November 24, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO
-
Publication number: 20220363684Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: January 7, 2022Publication date: November 17, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 11479550Abstract: A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EP4 receptor antagonistic activity, in preventing and/or treating disease caused by activation of an EP4 receptor.Type: GrantFiled: May 21, 2018Date of Patent: October 25, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaki Asada, Kousuke Tani, Satonori Higuchi
-
Publication number: 20220332825Abstract: A PD-1/CD4 bispecific protein for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases, hematological cancer and the like, which can reduce the induction of cytokine production or release upon administration, and thus is expected to inhibit the development of infusion reactions or cytokine release syndrome after administration.Type: ApplicationFiled: August 7, 2020Publication date: October 20, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA
-
Patent number: 11471436Abstract: A compound represented by general formula (I) wherein all the symbols are as defined in the specification has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e. g., neurodegenerative disease such as schizophrenia.Type: GrantFiled: December 3, 2015Date of Patent: October 18, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kensuke Kusumi, Haruto Kurata, Atsushi Naganawa, Yasuyo Kodera, Yuichi Inagaki, Hiroya Takizawa, Mark Allan Wolf, Joseph Raker
-
Publication number: 20220306640Abstract: A compound of formula (I-a): wherein the symbols are defined in the specification, and which has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.Type: ApplicationFiled: September 4, 2020Publication date: September 29, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Yota NISHIOKA, Masakuni KURONO, Rena NISHIZAWA, Balachandra BANDODKAR, Xuechao GAO, Zhilong WAN, Ranran LV, Kevin DOYLE, Michael GOLDSMITH
-
Publication number: 20220289751Abstract: The compound disclosed is a KDM5 inhibitor represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification, or a salt thereof, and is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.Type: ApplicationFiled: July 16, 2020Publication date: September 15, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akito KAKUUCHI, Shuhei UMEMURA, Mats SVENSSON, Anatoly RUVINSKY, Daigo INOYAMA, Goran KRILOV, Hidenori TAKAHASHI, Kyle KONZE, Andreas VERRAS, Simon CRUMPLER, Maelle VALLADE, Calum MACLEOD, James N. SANDERSON, Richard J. BULL, Simon GAINES
-
Publication number: 20220283167Abstract: A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.Type: ApplicationFiled: August 4, 2020Publication date: September 8, 2022Applicants: ONO PHARMACEUTICAL CO., LTD., NATIONAL CANCER CENTERInventors: Hiroyoshi NISHIKAWA, Yukiya OHYAMA, Atsushi HONDA, Atsushi OYAGI, Toru KAKINUMA, Masayuki MURATA
-
Publication number: 20220281977Abstract: A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.Type: ApplicationFiled: July 29, 2020Publication date: September 8, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER
-
Publication number: 20220227887Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.Type: ApplicationFiled: June 10, 2020Publication date: July 21, 2022Applicants: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITYInventors: Taku OKAZAKI, Daisuke SUGIURA, II-mi OKAZAKI, Shiro SHIBAYAMA
-
Publication number: 20220204468Abstract: An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.Type: ApplicationFiled: March 15, 2022Publication date: June 30, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaki ASADA, Keisuke HANADA, Satonori HIGUCHI, Atsushi NAGANAWA, Yasuhiro TAKEDA
-
Publication number: 20220185885Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.Type: ApplicationFiled: April 3, 2020Publication date: June 16, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER, Robertus Cornelis ROOVERS
-
Publication number: 20220177474Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: ApplicationFiled: February 24, 2022Publication date: June 9, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 11319296Abstract: An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.Type: GrantFiled: September 19, 2019Date of Patent: May 3, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Masaki Asada, Keisuke Hanada, Satonori Higuchi, Atsushi Naganawa, Yasuhiro Takeda
-
Publication number: 20220117933Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.Type: ApplicationFiled: December 28, 2021Publication date: April 21, 2022Applicants: Eisai R&D Management Co., Ltd., Ono Pharmaceutical Co., Ltd.Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
-
Patent number: 11292795Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: September 16, 2020Date of Patent: April 5, 2022Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20220089532Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).Type: ApplicationFiled: December 7, 2021Publication date: March 24, 2022Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shoji NOJIMA, Kenji SASAKI, Tohru KAMBE, Takashi KONEMURA, Yoshikazu GOTO